Related references
Note: Only part of the references are listed.T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
David T. Teachey et al.
CANCER DISCOVERY (2016)
A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma
A. K. Nowak et al.
ANNALS OF ONCOLOGY (2015)
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
Padmanee Sharma et al.
CELL (2015)
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
Dalil Hannani et al.
CELL RESEARCH (2015)
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Elizabeth Buchbinder et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
Dirk Schadendorf et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Christina Twyman-Saint Victor et al.
NATURE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
Rafael Winograd et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Immune Activation and a 9-Year Ongoing Complete Remission Following CD40 Antibody Therapy and Metastasectomy in a Patient with Metastatic Melanoma
David L. Bajor et al.
CANCER IMMUNOLOGY RESEARCH (2014)
A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2013)
Agonistic CD40 Antibodies and Cancer Therapy
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2013)
Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma
Antoni Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
Robert H. Vonderheide et al.
ONCOIMMUNOLOGY (2013)
The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice
Ronald P. Gladue et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
Marieke F. Fransen et al.
CLINICAL CANCER RESEARCH (2011)
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Gregory L. Beatty et al.
SCIENCE (2011)
Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
Jens Rueter et al.
CANCER BIOLOGY & THERAPY (2010)
Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
Luis H. Camacho et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
Erica L. Carpenter et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Phase 1, pharmacokinetic (PK) and pharmacodynamic (PD) study of oral alvespimycin (A; KOS-1022; 17-DMAG): Two different schedules in patients with advanced malignancies
K. T. Flaherty et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model
T. B. Hunter et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2007)
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
Robert H. Vonderheide et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prospect of targeting the CD40 pathway for cancer therapy
Robert H. Vonderheide
CLINICAL CANCER RESEARCH (2007)
Giving blood: a new role for CD40 in tumorigenesis
Stephan Bergmann et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
D Ito et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
